Renalytix shares slump as revenue guidance revised after Tempus deal
Renalytix PLC shares fell on Tuesday as it revised down its revenue guidance for financial 2026.
The London-based diagnostics company said it expects to report $8.4 million revenue in financial 2026, down from previous guidance for revenue of $8.5 million in its March half year report.
Shares in Renalytix ended down 11% at 8.95 pence in London on Tuesday.
It expects revenue of $19.0 million in financial 2027, up from the previous outlook of $17.5 million.
Renalytix set expectations for revenue of $42.0 million in financial 2028.
The company said these targets reflect the ‘anticipated positive revenue impact’ from its new collaboration agreement with Tempus AI Inc.
‘The board of directors are currently considering the long-term positive impact of the Tempus collaboration and the company will provide further updates regarding forward revenue guidance as appropriate, as the two parties execute implementation into hospital systems and other healthcare providers,’ the company said.
Copyright 2025 Alliance News Ltd. All Rights Reserved.